Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues

Cancer Research

Volumn 63, Issue 14, 2003, Pages 3955-3957

  Gorden, Alexis ^a   Osman, Iman ^a   Gai, Weiming ^a   He, Dan ^a   Huang, Weiqing ^b   Davidson, Anne ^b   Houghton, Alan N ^c   Busam, Klaus ^c   Polsky, David ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; RAF PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BASE PAIRING; CONTROLLED STUDY; EXON; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; ONCOGENE N RAS; PRIORITY JOURNAL;

EXONS; GENES, RAS; HUMANS; MELANOMA; MUTATION; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR CELLS, CULTURED;

EID: 0042173193     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Howe, H. L., Wingo, P. A., Thun, M. J., Ries, L. A., Rosenberg, H. M., Feigal, E. G., and Edwards, B. K. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl. Cancer Inst. (Bethesda), 93: 824-842, 2001.
2. Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., Dreno, B., Henz, M., Schadendorf, D., Kapp, A., Weiss, J., Fraass, U., Statkevich, P., Muller, M., and Thatcher, N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol., 18: 158-166, 2000.
3. Sun, W., and Schuchter, L. M. Metastatic melanoma. Curr. Treat. Options Oncol., 2: 193-202, 2001.
4. Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., and Slamon, D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-over-expressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16: 2659-2671, 1998.
5. Dagher, R., Cohen, M., Williams, G., Rothmann, M., Gobburu, J., Robbie, G., Rahman, A., Chen, G., Staten, A., Griebel, D., and Pazdur, R. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8: 3034-3038, 2002.
6. Peyssonnaux, C., and Eychene, A. The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell, 93: 53-62, 2001.
7. Martindale, J. L., and Holbrook, N. J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol., 192: 1-15, 2002.
8. Govindarajan, B., Bai, X., Cohen, C., Zhong, H., Kilroy, S., Louis, G., Moses, M., and Arbiser, J. L. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J. Biol. Chem., 278: 9790-9795, 2003.
9. Cohen, C., Zavala-Pompa, A., Sequeira, J. H., Shoji, M., Sexton, D. G., Cotsonis, G., Cerimele, F., Govindarajan, B., Macaron, N., and Arbiser, J. L. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin. Cancer Res., 8: 3728-3733, 2002.
10. Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Van Belle, P., Elder, D. E., and Herlyn, M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res., 63: 756-759, 2003.
11. Demunter, A., Stas, M., Degreef, H., De Wolf-Peeters, C., and van den Oord, J. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Investig. Dermatol., 117: 1483-1489, 2001.
12. Albino, A. P., Nanus, D. M., Mentle, I. R., Cordon-Cardo, C., McNutt, N. S., Bressler, J., and Andreeff, M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene, 4: 1363-1374, 1989.
13. Omholt, K., Karsberg, S., Platz, A., Kanter, L., Ringborg, U., and Hansson, J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin. Cancer Res., 8: 3468-3474, 2002.
14. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C., Wooster, R., Stratton, M. R., and Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature (Lond.), 417: 949-954, 2002.
15. Brose, M. S., Volpe, P., Feldman, M., Kumar, M., Rishi, I., Gerrero, R., Einhom, E., Herlyn, M., Minna, J., Nicholson, A., Roth, J. A., Albelda, S. M., Davies, H., Cox, C., Brignell, G., Stephens, P., Futreal, P. A., Wooster, R., Stratton, M. R., and Weber, B. L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res., 62: 6997-7000, 2002.
16. Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., and Meltzer, P. S. High frequency of BRAF mutations in nevi. Nat. Genet., 33: 19-20, 2003.
17. Papp, T., Pemsel, H., Zimmerman, R., Bastrop, R., Weiss, D., and Schiffmann, D. Mutational analysis of the N-ras, p53, p161NK4a. CDK4, and MCIR genes in human congenital melanocytic naevi. J. Med. Genet., 36: 610-614, 1999.
18. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p161NK4a. Cell, 88: 593-602, 1997.